NCT06822114

Substance Balance Trial of Methoxyethyl Etomidate Hydrochloride

Substance Balance of [14C]ET-26 in Healthy Chinese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Ahon Pharmaceutical Co., Ltd. · Academic / Other
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study was a single-center, single-dose, open-label design with 6-8 healthy adult male subjects to evaluate the body material balance of \[14C\]ET-26. Each subject received a single intravenous injection of \[14C\]ET-26 at a dose of 50 µCi/48 mg. Blood, urine, and stool samples were collected at specified times during the study. The pharmacokinetic parameters were calculated, and the distribution of total radioactivity in venous whole blood and plasma was analyzed. The excretion rate and pathway were analyzed. The metabolic pathway and elimination pathway of ET-26 in human body were analyzed.

Conditions

• Pharmacokinetics

Interventions

Type	Name	Description
DRUG	Methoxyethyl Etomidate Hydrochloride	The dose is 50 μCi/48 mg，in the fasting state, a single intravenous injection was given slowly

Timeline

• Start date: 2023-07-17
• Primary completion: 2023-07-31
• Completion: 2023-07-31
• First posted: 2025-02-12
• Last updated: 2025-02-14

Locations

1 site across 1 country: China